|
2023 Conference Publication A prohibitin-targeting drug modifies aspects of disease in a mouse model of Sanfilippo syndromeHemsley, Kim M., Beard, Helen, Doherty, Gareth G., Mubarokah, Siti, Nazri, Nazzmer and Ferro, Vito (2023). A prohibitin-targeting drug modifies aspects of disease in a mouse model of Sanfilippo syndrome. WORLDSymposiumTM 2023 19th Annual Research Meeting & Scientific Sessions, Orlando, FL United States, 22 - 26 February 2023. Waltham, MA United States: Academic Press. doi: 10.1016/j.ymgme.2022.107145 |
|
2015 Conference Publication Synthesis of steroid conjugates for targeted liposomal delivery of RNA-based therapiesHuong Nguyen, and Ferro, Vito (2015). Synthesis of steroid conjugates for targeted liposomal delivery of RNA-based therapies. WASHINGTON: AMER CHEMICAL SOC. |
|
2013 Conference Publication Micrornas as novel anti-angiogenesis therapeutic targetsPlummer, Prue N., Balsara, Spenta, Umer, Brittany, Taft, Ryan, Ferro, Vito, Mattick, John S., Swarbrick, Alex, McMillan, Nigel, Mittal, Vivek and Mellick, Albert S. (2013). Micrornas as novel anti-angiogenesis therapeutic targets. 8th Meeting of the Australasian GeneTherapy-Society, Sydney, NSW Australia, 08-10 May 2013. Hoboken, NJ United States: John Wiley and Sons Inc.. doi: 10.1002/jgm.2740 |
|
2013 Conference Publication Nanoparticle Delivery of Rna-Based Therapy to Modulate Tumour Vasculature: as a Next Generation Anticancer TherapyPlummer, Prue N., Balsara, Spenta, Ferro, Vito, Mittal, Vivek and Mellick, Albert S. (2013). Nanoparticle Delivery of Rna-Based Therapy to Modulate Tumour Vasculature: as a Next Generation Anticancer Therapy. 8th Meeting of the Australasian-Gene-Therapy-Society, Sydney Australia, 08-10 May 2013. Hoboken, NJ United States: Jossey Bass, Ed. and Pub.. doi: 10.1002/jgm.2740 |
|
2007 Conference Publication Heparan sulfate mimetics - potent angiogenesis inhibitors for cancer therapyDredge, K, Davis, K, Liu, L, Johnstone, K, Handley, P, Wimmer, N, Bytheway, I, Hammond, E, Li, CP, Rowley, J, Ferro, V and Gautam, A (2007). Heparan sulfate mimetics - potent angiogenesis inhibitors for cancer therapy. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, San Francisco, CA, United States, 22-26 October 2007. Philadelphia, PA, United States: American Association for Cancer Research. |
|
2005 Conference Publication PI-88, a heparanase inhibitor showing promising evidence of patient benefit in phase II clinical trials.Gautam, AM, Ferro, V, Wilson, EA, Freeman, C and Parish, C (2005). PI-88, a heparanase inhibitor showing promising evidence of patient benefit in phase II clinical trials.. AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics, Philadelphia Pa, Nov 14-18, 2005. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. |
|
2001 Conference Publication Pharmacokinetics of [35s] PI-88 in ratsCreese, B., Ferro, V., King, A. R., Mardon, K. M., Dickinson, R. G., Punler, M.J. and Dodds, H. (2001). Pharmacokinetics of [35s] PI-88 in rats. Annual Scientific Meeting of ASCEPT, Dunedin NZ, 3-5 December 2001. Melbourne: ASCEPT. |
